While the phase III trial success rate for drugs who have successfully completed phase II is overall above 50% it varies depending on the therapeutic field. Eg for oncology drugs it is only around 35% whereas for ophthalmic drugs it is almost 75%! With respect to the Carlyle group they report a success rate of 86% for the phase III trial companies they’ve invested in.
Ann: Opthea secures up to US$170m in non-dilutive financing, page-20
-
- There are more pages in this discussion • 16 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
78.0¢ |
Change
-0.010(1.27%) |
Mkt cap ! $960.2M | |||
| Open | High | Low | Value | Volume |
| 79.0¢ | 79.5¢ | 74.5¢ | $2.420M | 3.109M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1000 | 77.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 78.0¢ | 77447 | 1 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| OPT (ASX) Chart |